Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | PPARD | Q03181 | 5/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5565041 | 0.88 | PTGDR2 (0.51) | PTGDR2MAPTPPARGPPARA | |
| SCHEMBL5646670 | 0.82 | PPARD (0.52) | FFAR4FFAR1PTGDR2MAPTPPARG | |
| SCHEMBL5569708 | 0.80 | FFAR4 (0.48) | FFAR4FFAR1MAPTPPARGPPARD | |
| SCHEMBL6390211 | 0.78 | PPARA (0.48) | FFAR4FFAR1PTGDR2HPGDPPARG | |
| SCHEMBL5570821 | 0.78 | VDR (0.41) | FFAR4FFAR1HPGD | |
| SCHEMBL11847623 | 0.78 | PPARA (0.59) | PTGDR2MAPTPPARGPPARA | |
| SCHEMBL5565476 | 0.78 | VDR (0.51) | FFAR4FFAR1HPGD | |
| SCHEMBL29061885 | 0.77 | FFAR4 (0.48) | FFAR4FFAR1MAPTPPARGPPARD | |
| SCHEMBL5565459 | 0.77 | VDR (0.53) | — | |
| SCHEMBL5650512 | 0.75 | PPARD (0.51) | FFAR4FFAR1PTGDR2PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | disclosed |
| EP-1537065-B1 | ANALOGUES OF VITAMIN D | GALDERMA RES & DEV (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | FFAR4 347/4885FFAR1 290/4885PTGDR2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.